Home

IS/ISO 15197 (2003): In Vitro DiAGNOSTIC Test Systems

1. The design of the blood glucose monitoring system shall take into consideration ergonomic and relevant human factors for the following a ease of operation b ease of maintenance c protection from wear and tear that might typically be encountered in the use environment d readability of the measured results e unambiguous messages to the user e g low battery or low result rather than simply low NOTE 1 Blood glucose monitoring systems intended for self measurement may be used by laypersons with different physical and mental abilities IS ISO 15197 2003 NOTE 2 These systems are often transported by the individual users who may conduct measurements in a variety of settings NOTE 3 Itis not expected that a single blood glucose monitoring system will meet the needs of all possible users or settings 4 5 Risk analysis The requirements specified in ISO 14971 apply The manufacturer shall decide the acceptability of potential risks from knowledge of factors including but not limited to a intended use of the product b users skills and limitations c protection against unintentional change of essential parameters e g units reported or d influence of interfering substances NOTE Guidelines for evaluating potentially interfering substances are found in NCCLS EP7 AB1 In performing risk analysis the manufacturer shall evaluate the e probability of occurrence of a failure e g insu
2. 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ISSO 15197 2003 Bibliography Evaluation protocol for self blood glucose monitoring devices Agence Fran aise de Securit Sanitaire des Produits de Sant previously Agence du M dicament France April 1998 Consensus statement on self monitoring of blood glucose American Diabetes Association Diabetes Care 10 1 1987 pp 95 99 Self monitoring of blood glucose American Diabetes Association Diabetes Care 17 1 1994 pp 81 86 CSA Z316 4 94 Performance specifications for portable whole blood glucose monitor systems for use in diabetes management Canadian Standards Association March 1994 Comprehensive Chemistry Survey Program College of American Pathologists USA 1996 Whole Blood glucose Proficiency Survey Program College of American Pathologists USA 1997 Kost G J et al Multicenter study of oxygen insensitive handheld glucose point of care testing in critical care hospital ambulatory patients in WA United States and Canada Crit Care Med 3 1998 pp 581 590 Reactive strip assessment protocol for determination of glucose in blood Instituto Mexicano del Seguro Social Mexico 1998 TESTA M A and SIMONSON D C Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus JAMA 280 17 1998 pp 1490 1496 LEROUXx M and SESHIA M M K Glucose meter
3. User studies shall be conducted using at least three different reagent lots 8 2 Evaluation sites Blood glucose monitoring systems for self testing shall be evaluated in a setting that allows the lay user to perform the measurements without outside influence i e as described in 8 1 Rationale for the selection of evaluation sites shall be documented The evaluation may be conducted at multiple sites 8 3 User evaluation Study participants shall be given the product instructions for use and any training materials that are routinely provided with the blood glucose monitoring system After reviewing the materials the users shall perform their own fingersticks and test themselves using the blood glucose monitoring system Immediately after the user s self test the investigation site s trained healthcare professional shall measure the user s blood with the blood glucose monitoring system Within 5 min a second blood sample shall be collected The reference glucose concentrations shall be determined by the manufacturer s measurement procedure i e a selected or standing measurement procedure or by another validated measurement procedure that has been shown to produce equivalent results A routine glucose measurement procedure e g in a hospital or outpatient clinic laboratory that is validated for precision and trueness by comparison to the manufacturer s selected or standing measurement procedure may be used to assign the refe
4. 34 GMGIPN 61 BIS ND 2010 300 Bureau of Indian Standards BIS is a statutory institution established under the Bureau of Indian Standards Act 1986 to promote harmonious development of the activities of standardization marking and quality certification of goods and attending to connected matters in the country Copyright BIS has the copyright of all its publications No part of the these publications may be reproduced in any form without the prior permission in writing of BIS This does not preclude the free use in the course of implementing the standard of necessary details such as symbols and sizes type or grade designations Enquiries relating to copyright be addressed to the Director Publications BIS Review of Indian Standards Amendments are issued to standards as the need arises on the basis of comments Standards are also reviewed periodically a standard alongwith amendments is reaffirmed when such review indicates that no changes are needed if the review indicates that changes are needed it is taken up for revision Users of Indian Standards should ascertain that they are in possession of the latest amendments or edition by referring to the latest issue of BIS Catalogue and Standards Monthly Additions This Indian Standard has been developed from Doc No MHD 16 0059 Amendments Issued Since Publication Amend No Date of Issue Text Affected BUREAU OF INDIAN STANDARDS Headquarters Manak Bhavan 9
5. for blood glucose monitoring devices intended for self testing in addition to the requirements of 6 4 If risk analysis see 4 5 shows that exposure to higher levels of radiation or electrostatic discharge presents an unacceptable risk to the user then the device shall be tested at these higher levels A 2 Immunity test requirements A 2 1 Radiated immunity The requirements specified in IEC 61000 4 3 apply In addition immunity against radiated frequencies shall be extended to the frequency range up to 2 5 GHz at a test level of 3 V m A 2 2 Electrostatic discharge immunity The requirements specified in IEC 61000 4 2 apply For air discharge electrostatic discharge immunity shall be demonstrated at test levels of 2 kV 4 kV and 8 kV For contact discharge electrostatic discharge immunity shall be demonstrated at test levels of 2 kV 4 kV and 6 kV A 3 System test requirements If other equipment is connected to the meter or can be connected to the meter the resulting system shall also fulfil the EMC requirements When determining system testing requirements the manufacturer shall consider whether or not it is possible to perform a measurement while the system is connected System configurations specified by the manufacturer or foreseeable system configurations identified by risk analysis shall be tested as described in A 2 if they allow the user to perform a glucose measurement System test requirements may not apply
6. Bahadur Shah Zafar Marg New Delhi 110002 Telephones 2323 0131 2323 3375 2323 9402 Website www bis org in Regional Offices Telephones Central Manak Bhavan 9 Bahadur Shah Zafar Marg 2323 7617 NEW DELHI 110002 2323 3841 Eastern gt 1 14 C I T Scheme VII M V I P Road Kankurgachi 2337 8499 2337 8561 KOLKATA 700054 l 2337 8626 2337 9120 Northern SCO 335 336 Sector 34 A CHANDIGARH 160022 260 3843 1260 9285 Southern 2 CLT Campus IV Cross Road CHENNAI 600113 2254 1216 2254 1442 2254 2519 2254 2315 Western Manakalaya E9 MIDC Marol Andheri East 2832 9295 2832 7858 MUMBAI 400093 2832 7891 2832 7892 Branches AHMEDABAD BANGALORE BHOPAL BHUBANESHWAR COIMBATORE DEHRADUN FARIDABAD GHAZIABAD GUWAHATI HYDERABAD JAIPUR KANPUR LUCKNOW NAGPUR PARWANOO PATNA PUNE RAJKOT THIRUVANANTHAPURAM VISAKHAPATNAM oana o aaa o o a a a amaaa a Iaa PRINTED BY GENERAL MANAGER GOVT OF INDIA PRESS NASHIK 422 006 oLoZz aN Sia
7. L lt 75 mg dL and within 20 at glucose concentrations gt 4 2 mmol L gt 75 mg dL NOTE 1 The minimum acceptable accuracy criteria are based on the medical requirements for glucose monitoring See the Introduction for additional information 23 ISSO 15197 2003 NOTE 2 The criteria apply to system accuracy evaluations in which users have received proper training the device has been properly maintained and required adjustment and contro procedures have been followed in accordance with the manufacturer s instructions for use 7 4 2 Data presentation Results shall be presented separately for the glucose concentration intervals lt 4 2 mmol L lt 75 mg dL and gt 4 2 mmol L gt 75 mg dL because different criteria apply a For glucose concentrations lt 4 2 mmol L 75 mg dL results shall be expressed as the percentage of values falling within the following intervals 0 28 mmol L 5 mg dL 0 56 mmol L 10 mg dL and 0 83 mmol L 15 mg dL b For glucose concentrations gt 4 2 mmol L 75 mg dL results shall be expressed as the percentage of values falling within the following intervals 5 Yo 10 Yo 15 Yo and 20 Yo The results shall be presented in a table for each concentration interval The recommended format is given in the Example and Tables 4 and 5 below EXAMPLE Tables 4 and 5 illustrate the presentation of results for the evaluation illustrated in 7 3 3 2 and 7 3 3 3 in which 200
8. be substituted see below The glucose concentrations shall be distributed as specified in Table 3 Glucose concentrations shall be determined by the blood glucose monitoring system Once a concentration category is filled no more samples shall be added to that category Table 3 Glucose concentrations of samples for system accuracy evaluation Percentage of Glucose concentration samples mmol L mg dL lt 2 8 lt 50 2 8 to 4 3 50 to 80 4 4 to 6 7 80 to 120 11 2 to 16 6 201 to 300 16 7 to 22 2 301 to 400 Only unaltered capillary blood samples shall be used for glucose concentrations of 2 8 mmol L to 22 2 mmol L 50 mg dL to 400 mg dL If necessary to obtain sufficient samples in the lowest and highest concentration intervals glucose concentrations may be adjusted as follows To obtain additional samples with glucose lt 2 8 mmol L lt 50 mg dL capillary blood samples should be collected with an appropriate anticoagulant and incubated to allow glucose to hydrolyse The incubation conditions e g temperature to produce samples compatible with the system e g without haemolysis shall be determined by the manufacturer To obtain additional samples with glucose gt 22 2 mmol L gt 400 mg dL capillary blood samples should be collected with an appropriate anticoagulant and then supplemented with glucose Commutability of adjusted samples with the system being evaluated shall be v
9. capable of delivering sample volumes within the manufacturer s recommended interval may be used to simulate routine sample application c Repeat step b for each sample d Repeat steps b and c once each day with each of the nine remaining meters and vials or packages for a total of ten days The same vial package is used for each meter throughout the evaluation period e Calculate the mean value standard deviation and CV for each meter from the ten measurements f Calculate the grand mean the pooled standard deviation with 95 confidence interval and the pooled CV The standard deviation and CV are measures of the intermediate precision of a single system over multiple days 17 ISSO 15197 2003 If the evaluation included multiple lots and or users the lot to lot and user to user variability may be determined as well as the within meter intermediate precision 7 2 4 Data analysis and presentation for repeatability and intermediate precision The mean standard deviation and coefficient of variation for repeatability and intermediate precision shall be calculated using documented statistical procedures The analysis of variance is the preferred method for calculating intermediate precision The following information shall be reported a glucose concentration of each sample b mean of the observed glucose results for each sample c repeatability standard deviation with 95 confidence interval and coefficient of vari
10. description and use of the medical device but excluding shipping documentation and promotional material NOTE 1 Adapted from EN 1041 1998 NOTE 2 In some countries information supplied by the manufacturer is called labelling 3 8 instructions for use information supplied by the manufacturer with an in vitro diagnostic medical device concerning the safe and proper use of the reagent or the safe and correct operation maintenance and basic troubleshooting of the instrument NOTE 1 Adapted from EN 375 2001 and EN 591 2001 NOTE 2 _ Instructions for use for in vitro diagnostic reagents for self testing is described in EN 376 NOTE 3 Instructions for use for in vitro diagnostic instruments for self testing is described in EN 592 NOTE 4 Instructions for use may take the form of package insert sheets and or user manuals 3 9 intermediate precision precision under conditions intermediate between reproducibility conditions and repeatability conditions NOTE The concept of intermediate levels of precision is described in ISO 5725 3 1994 3 10 intermediate precision conditions conditions where independent test results are obtained with the same method on identical test items in the same location but where other variables such as operators equipment calibration environmental conditions and or time intervals differ NOTE Intended to measure precision in conditions leading to variability representative of actual use Quantitative measu
11. difference between the mean glucose concentration after the challenge and the mean glucose concentration before the challenge shall be calculated and compared to the acceptance criteria for bias b Repeatability the square root of the difference between the repeatability variance after the challenge and the repeatability variance before the challenge shall be calculated and compared to the acceptance criteria for repeatability 6 10 Mechanical resistance to shock vibration and impact 6 10 1 Vibration test protocol Perform the performance test described in 6 9 Perform the vibration test as specified in IEC 60068 2 64 1993 8 3 After vibration testing is complete repeat the performance test The requirements specified in IEC 60068 2 64 1993 8 3 apply 6 10 2 Drop test protocol To evaluate drop durability perform the performance test described in 6 9 Perform the drop test as specified in IEC 61010 1 2001 8 2 12 ISSO 15197 2003 After drop testing is complete repeat the performance test The requirements specified in IEC 61010 1 2001 8 2 apply 6 11 Equipment temperature exposure limits 6 11 1 High temperature test protocol Perform the performance test as described in 6 9 Place each meter in a sealed environmental chamber that can be monitored for internal temperature Increase the temperature to 50 C 2 C and leave at this temperature for 8 h in the sealed chamber Remove the meter from the environmental cha
12. if the design of the device prevents the user from performing glucose measurements when the meter is connected to other equipment A 4 Instructions for use The instructions for use see 5 2 shall include the following information a A statement that the equipment complies with applicable EMC emission requirements and that emissions of the energy used are low and not likely to cause interference in nearby electronic equipment 27 IS ISO 15197 2003 28 A statement that the equipment is tested for immunity to electrostatic discharge as specified in IEC 61000 4 2 Recommended mitigation measures that should be taken by the user to avoid incorrect operation or damage to the device EXAMPLE 1 Do not use this meter in a dry environment especially if synthetic materials are present Synthetic clothes carpets etc may cause damaging static discharges in a dry environment A statement that the equipment is tested for immunity to radio frequency interference at the frequency range and test levels specified in this International Standard Recommended mitigation measures that should be taken by the user to avoid radio frequency interference with specific examples EXAMPLE 2 Do not use this meter near cellular or cordless telephones walkie talkies garage door openers radio transmitters or other electrical or electronical equipment that are sources of electromagnetic radiation as these may interfere with the proper operation
13. of the container provided to protect reagent strips or sensors from exposure to air should be included in the instructions for use for reagents d the measurement interval indicating the upper and lower concentration limits within which the glucose results are accurate and reportable e the performance characteristics those related to system accuracy are based on the results of testing performed as described in Clause 7 stated in language that is understandable by the intended user and for system accuracy performance see 7 4 2 the manufacturer shall report for glucose concentrations lt 4 2 mmol L 75 mg dL the percentage of results within 0 28 mmol L 0 56 mmol L and 0 83 mmol L 5 mg dL 10 mg dL and 15 mg dL of the reference values for glucose concentrations gt 4 2 mmol L 75 mg dL the percentage of results within 5 Yo 10 Yo 15 Yo and 20 Yo of the reference values f any interfering substances sample conditions e g haemolysis icterus lipemia or physiological conditions e g changes in peripheral circulation known to affect the accuracy of results g the measurement procedure used to evaluate the performance characteristics of the system and a statement describing its traceability to a glucose reference measurement procedure or reference material of higher order h the reference interval for capillary blood glucose concentrations in nondiabetic individuals and the type of samples u
14. or the revision number 5 3 Labels for the reagent system and control material The reagent system and control material shall be identified by a label or labels The requirements specified in EN 376 apply In addition the following information shall be included on the label s a indication of the period of time during which the reagent should be used after the first opening of the immediate reagent container expressed as months and or days b areference to the instructions for use c the blood glucose meter to be used with the reagents Warning statements concerning use of the reagent system with the specified blood glucose meter and disposal of the reagent system after use should be included on the label to promote reliable measurement results and safe reagent disposal The language s of the country in which the reagents and control materials are distributed shall be used additional languages are optional IS ISO 15197 2003 5 4 Instructions for use for reagents and control material The requirements specified in EN 376 apply In addition the following information shall be included a an indication of how to access help from the manufacturer and or distributor b the specific blood glucose meter to be used with the reagent system and control material c the storage conditions e g temperature humidity exposure to light and other environmental factors a warning statement concerning the need to tightly seal the cap
15. use in nurseries error grid evaluates clinical accuracy Laboratory Medicine 25 9 1994 pp 592 595 NCCLS C30 A2 Point of Care Blood glucose Testing in Acute and Chronic Care Facilities Approved Guideline 2nd Ed NCCLS document ISBN 1 56238 471 6 NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 2002 WEISS S L CEMBROWSKI G S and Mazze R L Patient and physician analytic goals for self monitoring blood glucose instruments Am J Clin Path 102 5 1994 pp 611 615 The effect of intensive treatment of diabetes on the development and progression of long term complications in insulin dependent diabetes mellitus The Diabetes Control and Complications Trial Research Group DCCT NEJM 329 14 1993 pp 977 986 KOSCHINSKY T DANNEHL K and GRIES F A New approach to technical and clinical evaluation of devices for self monitoring of blood glucose Diabetes Care 11 1988 pp 619 629 TNO CMT 90 021 E Quality guideline for non implantable portable blood glucose monitors for self monitors TNO Center for Medical Technology Leyden The Netherlands February 1991 MDA evaluation reports United Kingdom Medical Devices Agency London For a complete list see www medical devices gov uk Review criteria for assessment of portable invasive blood glucose monitoring in vitro diagnostic devices which use glucose oxidase dehydrogenase or hexokinase methodology United States Food and Drug Administration Di
16. used for the x and y axes Slope and y intercept shall be calculated by a suitable regression analysis procedure The estimate of the deviation standard error s should be reported if linear regression is used The regression line and the line of identity v x shall be included on the plot NOTE 1 Regression analysis depends on the data meeting certain statistical assumptions For an evaluation of regression procedures for method comparison studies see Linnet 34 or St ckil34 NOTE 2 Bias can be calculated from the regression equation at selected glucose concentrations e g at medical decision concentrations See NCCLS EP9 A2I821 EXAMPLE A regression plot from an evaluation of a blood glucose monitoring system is illustrated below The two outer lines represent the acceptance criteria from 7 4 The regression line and the line of equality are superimposed 22 IS ISO 15197 2003 Meter glucose concentration mmol L 0 5 10 15 20 25 30 Reference glucose concentration mmol L y 0 984x 0 20 R 0 959 6 N 200 Figure 2 Regression plot 7 4 Minimum acceptable system accuracy 7 4 1 System accuracy requirement The minimum acceptable accuracy for results produced by a glucose monitoring system shall be as follows Ninety five percent 95 of the individual glucose results shall fall within 0 83 mmol L 15 mg dL of the results of the manufacturer s measurement procedure at glucose concentrations lt 4 2 mmol
17. users Otherwise the experiment shall be designed to evaluate the dependence of repeatability on these factors NOTE Refer to ISO 5725 2123 for guidelines for determining the repeatability of a measurement method 14 IS ISO 15197 2003 7 2 2 2 Samples The repeatability evaluation shall be performed with blood samples The preferred sample for evaluation of repeatability is venous blood Samples shall be prepared from human venous blood collected into tubes containing an anticoagulant specified in the instructions for use The packed cell volumes haematocrit shall be within 0 35 L L to 0 50 L L 35 to 50 Five samples with glucose concentrations in the intervals specified in Table 1 shall be used The glucose concentration of each sample shall be determined using the blood glucose monitoring system The glucose concentration in venous blood samples may be adjusted by supplementing the sample with an aqueous glucose solution prepared with a 0 9 saline solution The dilution should not significantly alter the sample matrix Spiked samples should be allowed to stand for at least 15 min before use to allow for complete mutarotation and equilibration of the D and L enantiomers A preservative that does not interfere with the glucose measurements e g maleimide fluoride or monoiodoacetate and is in accordance with the manufacturer s recommendations may be added to the sample in sufficient amount to minimize glycolysis To ach
18. FOR SELF TESTING IN MANAGING DIABETES MELLITUS ICS 11 100 BIS 2010 BUREAU OF INDIAN STANDARDS MANAK BHAVAN 9 BAHADUR SHAH ZAFAR MARG NEW DELHI 110002 May 2010 Price Group 11 ISSO 15197 2003 Surgical Disposables and Dressings Sectional Committee MHD 16 NATIONAL FOREWORD This Indian Standard which is identical with ISO 15197 2003 In vitro diagnostic test systems Requirements for blood glucose monitoring systems for self testing in managing diabetes mellitus issued by the International Organization for Standardization ISO was adopted by the Bureau of Indian Standards on the recommendation of the Surgical Disposables and Dressings Sectional Committee and approval of the Medical Equipment and Hospital Planning Division Council Blood glucose monitoring systems are in vitro diagnostic medical devices used predominantly by individuals affected by diabetes mellitus Diabetes mellitus is caused by a relative or absolute deficiency in insulin secretion or by insulin resistance leading to abnormal concentrations of glucose in the blood which may result in acute and chronic health complications When used properly a glucose monitoring system allows the user to monitor and take action to control the concentration of glucose present in the blood This standard is intended for blood glucose monitoring systems used by laypersons The primary objectives are to establish requirements that result in acceptable performance and to sp
19. OCKL D DEWITTE K and THIENPONT L M Validity of linear regression in method comparison studies is it limited by the statistical model or the quality of the analytical input data Clin Chem 44 11 1998 pp 2340 2346 Council Directive 98 79 EC of the European Parliament and of the Council of 27 October 1998 on In vitro Diagnostic Medical Devices Official Journal of the European Union L331 December 7 1998 38 39 40 41 IS ISO 15197 2003 NCCLS EP18 P Quality management for unit use testing Approved guideline NCCLS document ISBN 1 56238 391 4 NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 USA 1999 ISO 15194 2002 In vitro diagnostic medical devices Measurement of quantities in samples of biological origin Description of reference materials EN 1041 1998 Information supplied by the manufacturer with medical devices EN 591 2001 Instructions for use for in vitro diagnostic instruments for professional use 33 ISMSO 15197 2003 NATIONAL ANNEX A National Foreword A 1 BIS CERTIFICATION MARKING The product may also be marked with the Standard Mark A 1 1 The use of the Standard Mark is governed by the provisions of the Bureau of Indian Standards Act 1986 and the Rules and Regulations made thereunder The details of conditions under which the licence for the use of the Standard Mark may be granted to manufacturers or producers may be obtained from the Bureau of Indian Standards
20. The requirements specified in IEC 61010 1 2001 13 1 and 13 2 2 apply 6 8 Meter components The requirements specified in IEC 61010 1 2001 14 1 14 4 14 5 and 14 6 apply 6 9 Performance test The performance test shall be performed before and after each determination of mechanical resistance to shock vibration and impact see 6 10 and protection against exposure to temperature and humidity levels see 6 11 and 6 12 Pass fail criteria shall be based on the effect of the challenge on system bias and repeatability Prior to each performance test the blood glucose meter shall be equilibrated to 23 C 2 C The manufacturer s recommended control material or a suitable alternative should be used for the performance tests It may be difficult to separate the variability due to sample and reagent system Components from meter components This should be taken into consideration when designing the test and developing acceptance criteria A check strip which simulates a reagent strip after reaction with glucose or other similar alternative to analysing the manufacturer s recommended control material may be used to verify that measurement system performance has not been affected Test samples shall be measured in the order specified in the protocol Mean glucose concentration and repeatability shall be calculated before and after each challenge and the difference compared to the acceptance criteria a Mean glucose concentration the
21. access help b product name or designation c intended purpose of the device d the principle of the method e measurement procedures and or calibrator materials traceability to a reference measurement procedure and or reference material of higher order should be indicated if applicable used by the manufacturer to establish and evaluate performance characteristics f the type of samples used by the manufacturer for calibration e g blood or plasma g proper reagent system to be used h measurement procedure to be followed when using the device including the sequence of adjustment e g use of a number code strip code chip etc measurement and verification and the allocated time intervals between them the sequence of steps to prepare the instrument for the measurement to execute the measurement including the amount and recommended appearance of the sample and to maintain the instrument after the measurement the measurement units reported by the device e g mmol L or mg dL whether reported results are equivalent to blood or plasma results advice on how to proceed when an error message is generated by the meter i environmental conditions e g temperature and humidity range under which the system shall be used 4 61 BIS ND 10 ISHSO 15197 2003 j detailed procedure to be followed by the user in adjusting the device if applicable k detailed user control procedures including i
22. ample to be detected and its concentration measured 3 20 repeatability precision under repeatability conditions ISO 3534 1 1993 3 61 BIS ND 10 ISHSO 15197 2003 3 21 repeatability conditions conditions where independent test results are obtained with the same method on identical test items in the same laboratory by the same operator using the same equipment within short intervals of time ISO 3534 1 1993 NOTE 1 Essentially unchanged conditions intended to represent conditions resulting in minimum variability of test results NOTE 2 For the purposes of this International Standard laboratories should be interpreted as locations 3 22 reproducibility precision under reproducibility conditions ISO 3534 1 1993 3 23 reproducibility conditions conditions where test results are obtained with the same method on identical test items in different laboratories with different operators using different equipment ISO 3534 1 1993 NOTE 1 Completely changed conditions intended to represent conditions resulting in maximum variability of test results NOTE 2 For the purposes of this International Standard laboratories should be interpreted as locations 3 24 system accuracy closeness of agreement of a set of representative test results from a measuring system and their respective reference values NOTE 1 The term accuracy when applied to a set of test results involves a combination of ran
23. asurements by the manufacturer s measurement procedure If the manufacturer s measurement procedure is designed for plasma samples the plasma preparation procedure e g centrifugation at 1 000 g for 10 min to remove cells shall be performed for each sample d Take two reagent system units out of vial package number one and measure the glucose concentration in the sample using two different meters 20 e g ISSO 15197 2003 Samples shall be applied to the reagent system unit in the same manner as described in the manufacturer s instructions e g directly from the subjects skin puncture If adjusted samples are used as described in 7 3 1 2 they shall be applied in a manner that simulates the procedure specified in the manufacturer s instructions for use taking into account possible influences such as sample temperature Change vials or packages every ten subjects angy ensure that reagent system units from all vials are used in the evaluation Record the results Repeat step c to obtain a second result from the manufacturer s measurement procedure Evaluate the results from the manufacturer s measurement procedure to verify sample stability If these results demonstrate the effect of drift based on predetermined stability criteria e g change between the first and last results gt 4 at glucose gt 5 5 mmol L 100 mg dL or gt 0 22 mmol L 4 mg dL at glucose lt 5 5 mmol L 100 mg dL then the results for that su
24. ation CV for each glucose concentration above 4 2 mmol L 75 mg dL and standard deviation with 95 confidence interval for each glucose concentration below 4 2 mmol L 75 mg dL d intermediate standard deviation with 95 confidence interval and coefficient of variation CV for each glucose concentration above 4 2 mmol L 75 mg dL and standard deviation with 95 Yo confidence interval for each glucose concentration below 4 2 mmol L 75 mg dL e summary of any outliers guidelines for identifying outliers are found in ISO 5725 2 1994l23 and in NCCLS EP5 A 9l identified and excluded from statistical analysis including the method of identification and the results of the investigation f references to the statistical analysis procedures 7 3 System accuracy evaluation 7 3 1 Requirements 7 3 1 1 General System accuracy shall be evaluated with at least 100 different subjects over at least ten days The evaluation shall be conducted in actual conditions of use so that the effects of systematic error bias and random error imprecision that would be experienced by individual users will be included Individual measurements from the blood glucose monitoring system shall be compared to reference glucose concentration values determined by the manufacturer s measurement procedure i e a selected or standing measurement procedure or by another validated measurement procedure that has been shown to produce equivalent results A rou
25. bject shall not be included The rejected sample shall be replaced with another sample in the same glucose concentration interval Drift criteria should be related to the intermediate precision capability of the measurement procedure If criteria are too tight samples will be discarded unnecessarily If too loose the apparent uncertainty of the measurement procedure will be inflated Obtain a sample from the next subject and repeat steps b to f 7 3 3 Data analysis and presentation for system accuracy 7 3 3 1 General Results shall be plotted and analysed using one of the procedures described below The following information shall be reported a b c d e f total number of samples analysed range of glucose concentrations plot of the data summary of the statistics with confidence intervals summary of any outliers guidelines for identifying outliers are found in ISO 5725 2 1994 23 and in NCCLS EP9 A2 32 identified and excluded from Statistical analysis including the method of identification and the results of the investigation Outlier data may not be eliminated from the data set to be used in determining minimum acceptable accuracy 7 4 1 but should be excluded from the calculation of parametric statistics to avoid distorting central tendency and dispersion estimates Outlier data should be plotted with a different symbol references for the statistical analysis procedures If results of the blood glu
26. blication as an Indian Standard without deviations Certain conventions are however not identical to those used in Indian Standards Attention is particularly drawn to the following a Wherever the words International Standard appear referring to this standard they should be read as Indian Standard b Comma has been used as a decimal marker in the International Standard while in Indian Standards the current practice is to use a point as the decimal marker In this adopted standard reference appears to the following International Standard for which Indian Standard also exists The corresponding Indian Standard which is to be substituted in its place is listed below along with its degree of equivalence for the edition indicated International Standard Corresponding Indian Standard Degree of Equivalence ISO 13485 2003 Medical devices IS 15579 2005 Medical devices Identical Quality management systems Quality management systems Requirements for regulatory purposes Requirements for regulatory purposes The technical committee has reviewed the provisions of the following International Standards referred in this adopted standard and has decided that they are acceptable for use in conjunction with this standard International Other Standard Title ISO 14971 2007 Medical devices Application of risk management to medical devices ISO 17511 2003 In vitro diagnostic medical devices Measurement of quant
27. ce to the BIS certification marking of the product Details of Miche is given in National Annex A For the purpose of deciding whether a particular requirement of this standard is complied with the final value observed or calculated expressing the result of a test or analysis shall be rounded off in accordance with IS 2 1960 Rules for rounding off numerical values revised The number of significant places retained in the rounded off value should be same as that of the specified value in this standard 2 61 BIS ND 10 ISSO 15197 2003 Indian Standard IN VITRO DIAGNOSTIC TEST SYSTEMS REQUIREMENTS FOR BLOOD GLUCOSE MONITORING SYSTEMS FOR SELF TESTING IN MANAGING DIABETES MELLITUS 1 Scope This International Standard specifies requirements for in vitro glucose monitoring systems that measure glucose concentrations in capillary blood samples and procedures for the verification and the validation of performance by the intended users These systems are intended for self testing by laypersons for management of diabetes mellitus This International Standard is applicable to manufacturers of such systems and those other organizations e g regulatory authorities and conformity assessment bodies having the responsibility for assessing the performance of these systems This International Standard does not provide a comprehensive evaluation of all possible factors that could affect the performance of these systems
28. cose monitoring system are reported in units of a different sample matrix e g plasma the manufacturer shall provide details of the conversion and supporting validation data to users upon request 7 3 3 2 System accuracy analysis The difference between individual results from the blood glucose monitoring system and the mean of the reference values shall be plotted as the dependent variable The mean of the reference values shall be plotted as the independent variable 21 IS ISO 15197 2003 Difference plots are the recommended approach for depicting system accuracy because statistical assumptions are minimal and the percentage of data points meeting the system accuracy criteria as well as estimating bias are easily calculated See NCCLS EP9 A2 82 or Bland and Altman 34 NOTE Plotting percentage difference against concentration at low concentrations is generally not suitable for the graphical evaluation of system accuracy EXAMPLE A plot of results from an evaluation of a blood glucose monitoring system is illustrated in Figure 1 The two bold lines represent the acceptance criteria from 7 4 Difference mmol L 0 Glucose concentration mmol L Figure 1 System accuracy plot 7 3 3 3 Regression analysis Individual results of the blood glucose monitoring system shall be plotted as the dependent variable and the mean of the duplicate reference values as the independent variable Identical scales and intervals shall be
29. d general terms in metrology VIM BIPM IEC IFCC ISO IUPAC IUPAP OIML 2nd ed 1993 l EN 375 2001 Information supplied by the manufacturer with in vitro diagnostic reagents for professional use EN 592 2002 Instructions for use for in vitro diagnostic instruments for self testing EN 13532 2002 General requirements for in vitro diagnostic medical devices for self testing NCCLS EPS A Evaluation of precision performance of clinical chemistry devices Approved guideline NCCLS document ISBN 1 56238 368 X NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 USA 1999 NCCLS EP7 A Interference testing in clinical chemistry Approved Guideline NCCLS document ISBN ISBN 1 56238 480 5 NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 USA 2002 NCCLS EP9 A2 Method comparison and bias estimation using patient samples Approved guideline 2nd Ed NCCLS document ISBN 1 56238 472 4 NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 USA 2002 LINNET K Evaluation of regression procedures for methods comparison studies Clinical Chemistry 1993 39 pp 424 432 BLAND J M and ALTMAN D G Statistical methods for assessing agreement between two methods of clinical measurement Lancet i 1986 pp 307 310 NCCLS EP21 P User estimation of total error for clinical laboratory methods Approved guideline NCCLS document ISBN 1 56238 456 2 NCCLS 940 West Valley Road Suite 1400 Wayne PA 19087 1898 USA 2002 ST
30. dentification of the appropriate control material to be used to assure that the blood glucose monitoring system is operating properly and advice on how to proceed if control results are not acceptable 1 type of sample to be used as well as any special conditions of collection and pretreatment m precautions to be taken against the risk of infection from prior use of the instrument n precautions to be taken regarding electrostatic discharge magnetic fields and other electrical conditions as well as exposure to temperature humidity and other environmental conditions as applicable see IEC 61010 2 101 2002 Clause 5 0 description and explanation of all symbols used on labels and in the instructions for use p guidance on action to be taken by the user as a consequence of the result including a reference to the instructions given by a physician and or other qualified healthcare provider and a warning not to deviate from these instructions on the basis of the result without first consulting the physician or other qualified healthcare provider advice on how to proceed if the result appears to be questionable to the user indication how the monitoring system alerts the user when the result is outside the measurement interval e g error messages fault notifications q information on the safe disposal of the system and its components where appropriate r the year and month of issue of the instructions for use and
31. dom error components and a common systematic error or bias component VIM 1993 NOTE 2 Reference values are assigned by a measurement procedure traceable to a reference measurement procedure of higher order NOTE 3 System accuracy may be expressed as the interval that encompasses 95 of the differences observed between the results of the system being evaluated and their reference values This interval also includes measurement uncertainty from the measurement procedure used to assign the reference values 3 25 traceability property of the result of a measurement or the value of a standard whereby it can be related to stated references usually national or international standards through an unbroken chain of comparisons all having stated uncertainties VIM 1993 6 10 3 26 trueness closeness of agreement between the average value obtained from a large series of test results and an accepted reference value ISO 3534 1 1993 NOTE The measure of trueness is usually expressed in terms of bias 3 2 IS ISO 15197 2003 3 27 type test test of one or more samples of equipment or parts of equipment made to a particular design to show that the design and construction meet one or more requirements of the applicable standard NOTE 1 Statistical sampling is not required for blood glucose monitoring equipment NOTE 2 Adapted from IEC 61326 3 28 user adjustment of blood glucose monitoring system procedure described in the ins
32. easing the number of meters in the experiment reduces the specific influence of each meter bias but can increase variability due to meter to meter effects intermediate precision If different subjects use the same meter cleaning the meter may be necessary to avoid the transfer of blood borne pathogens It is recommended that manufacturers validate an appropriate cleaning procedure and include cleaning information in the user s manual 7 3 1 5 Environment Measurements using the blood glucose monitoring system shall be performed at 23 C 5 C The measurement of capillary blood samples by the blood glucose monitoring system should preferably take place in a diabetes mellitus outpatient clinic or hospital setting The 10 C temperature interval covers the ambient temperatures that typically exist in these settings 7 3 2 Evaluation procedure The following procedure is the minimum experimental design to evaluate system accuracy It requires at least 100 subjects with glucose concentrations that span the measuring interval as specified in Table 3 This procedure may be modified to accommodate multiple reagent lots The reagent system units shall be taken from the same vial package for each sample Steps a to f shall be performed for each sample a Assign numbers to the vials or packages e g 1 to 10 b Obtain a sample of fresh capillary blood by skin puncture c Remove an aliquot of the sample for at least duplicate glucose me
33. ecify procedures for demonstrating conformance to this standard Performance criteria for blood glucose monitoring systems were established from the accuracy precision and trueness required for individual glucose results System accuracy criteria also known in the in vitro diagnostics IVD industry as total error criteria see NCCLS EP 21 P 35 are used in this standard because some of the metrological terms commonly used in this standard for example uncertainty would not be familiar to lay users System accuracy which is affected by systematic bias and measurement uncertainty describes the degree to which individual results produced by a glucose monitoring system agree with the true glucose values when the system is used as intended by laypersons The criteria for system accuracy are based on three considerations a The effectiveness of current technology for monitoring patients with diabetes mellitus as demonstrated in clinical outcome studies using state of the art monitoring devices b Recommendations of diabetes researchers as well as existing product standards and regulatory guidelines and c The state of the art of currently available eee as evidenced by the performance of existing commercial products In arriving at the performance criteria desirable goals has to be weighed against the capabilities of existing devices the current state of the art and their effectiveness in clinical outcome studies It was decided that o
34. ectromagnetic compatibility EMC Part 4 2 Testing and measurement techniques Electrostatic discharge immunity test IEC 61000 4 3 Electromagnetic compatibility EMC Part 4 3 Testing and measurement techniques Radiated radio frequency electromagnetic field immunity test IEC 61326 Electrical equipment for measurement control and laboratory use EMC requirements EN 376 Information supplied by the manufacturer with in vitro diagnostic reagents for self testing EN 13612 Performance evaluation of in vitro diagnostic medical devices EN 13640 Stability testing of in vitro diagnostic reagents 3 Terms and definitions For the purposes of this document the following terms and definitions apply 3 1 accuracy closeness of agreement between a test result and the accepted reference value ISO 3534 1 1993 NOTE 1 The term accuracy when applied to a set of test results involves a combination of random error components and a common systematic error or bias component VIM 1993 NOTE 2 For a measure of the accuracy of results of a blood glucose monitoring system see 3 24 3 2 bias difference between the expectation of the test results and an accepted reference value ISO 5725 1 1994 3 3 blood glucose monitoring system measuring system consisting of a portable instrument and reagents used for the in vitro monitoring of glucose concentrations in blood NOTE Blood glucose monitoring systems measure glucose
35. ed for its intended use NOTE ISO 17511 4 2 2 h shows the manufacturer s standing measurement procedure in the traceability chain 3 16 package insert instructions for use and other information for the reagent system or control material that is supplied within the package but not attached to any part of the package 3 17 packed cell volume volume fraction of the erythrocytes in blood NOTE 1 Expressed either as a decimal fraction SI or as a percentage conventional SI units L L are implied NOTE 2 Sometimes referred to as haematocrit after the instrument originally used to estimate packed cell volume 3 18 precision of measurement closeness of agreement between independent test results obtained under stipulated conditions ISO 3534 1 1993 NOTE 1 The degree of precision is expressed numerically by the statistical measures of imprecision of measurements such as standard deviation and coefficient of variation that are inversely related to precision Quantitative measures of precision depend on the stipulated conditions NOTE 2 Precision of a given measurement procedure is subdivided according to the specified precision conditions Particular sets of extreme conditions are termed repeatability 3 20 and reproducibility 3 22 3 19 reagent system part of the in vitro diagnostic medical device that produces a signal via a chemical or electrochemical reaction which allows the analyte e g glucose in a s
36. erified Aliquots shall be removed from each sample immediately before the first and immediately after the last measurement by the blood glucose monitoring system for duplicate measurement by the manufacturer s measurement procedure If this measurement procedure is not designed for blood samples and it does not specify a procedure to remove cells the aliquots of the sample shall be centrifuged at 1 000 g for 10 min immediately after collection to obtain plasma 19 IS ISO 15197 2003 7 3 1 3 Reagent system A lot or part of a lot of reagent system units shall be examined If a complete lot is not available the parts and status of the material shall be recorded At least 200 reagent system units from at least ten vials or packages shall be used Additional units from the same lot shall be available for additional measurements as needed A single lot of reagent system units may be used if characterization data have demonstrated that lot to lot variability is a minor source of the total variability Otherwise multiple reagent lots shall be included in the system accuracy evaluation 7 3 1 4 Meters Using more than one meter per subject may be necessary to minimize the time between duplicate measurements The procedure in 7 3 2 assumes each subject will use two different meters If more than two meters are used the meters shall be rotated through the protocol so that equal numbers of samples are measured with each meter NOTE Incr
37. fficient sample volume or incorrect test strip placement f probability of the system not detecting a failure and g consequences of an undetected failure NOTE This International Standard does not specify levels of risk and acceptability 4 6 User verification The design of the blood glucose monitoring system shall allow the user to check a correct functioning of the blood glucose monitoring system i e system control and b correct execution of the test including the sequence of the procedural steps NOTE User verification should be done at the time of use At the time of use means before during or immediately after the execution of the test User verification should be integrated into the test if reasonably possible User verification shall give unambiguous information 5 Information supplied by the manufacturer 5 1 Labels for the blood glucose meter The blood glucose meter shall be identified by labels including at a minimum the following information a name or trade name of the manufacturer and address of the manufacturer b product name or designation this information shall directly appear on a label affixed to the device c intended purpose a statement that the device is an in vitro diagnostic medical device for self testing shall be included as well as information regarding the reagent system to be used with the device IS ISO 15197 2003 d lot or serial number appearing directly on a label affixed
38. fications set for it In Clause 8 evaluations are design validation activities which are intended to provide assurance that system performance meets user requirements NOTE 2 _ The type of samples required for each evaluation is specified 7 2 Precision evaluation 7 2 1 General Repeatability and intermediate precision shall be evaluated against performance criteria derived from the system accuracy criteria in 7 3 The acceptance criteria shall be documented in the protocol The analysis of variance is the preferred statistical method to use when multiple factors are evaluated NOTE 1 Refer to ISO 5725 1221 for general principles regarding the evaluation of precision of a measurement method NOTE 2 The experiments can be designed to evaluate the effect of such factors as different lots different sample materials different users or other variables e g effect of temperature humidity 7 2 2 Repeatability evaluation 7 2 2 1 General Repeatability shall be evaluated at five glucose concentrations spread across the measuring interval Repeatability shall be measured over a short span of time not to exceed one day per meter with the same user meter and reagent lot The experiment shall be designed to minimize the effect of glucose instability in the sample The evaluation may be performed on a single lot and or by a single user if data have demonstrated that the repeatability of the system is not dependent on particular reagent lots and or
39. hen the results for that sample shall not be used and all measurements for that sample shall be repeated 7 2 3 Intermediate precision evaluation 7 2 3 4 General Intermediate precision shall be evaluated at three glucose concentrations The evaluation shall be designed to measure precision in normal conditions of use i e by an individual user across multiple days with the same meter and reagent system lot The evaluation shall be conducted with multiple meters and different users over at least ten days The evaluation may be performed on a single lot if data have demonstrated that intermediate precision including repeatability is not dependent on the reagent lot Otherwise multiple lots should be used and the experiment shall be designed to evaluate lot to lot variability NOTE Refer to ISO 5725 3 for guidelines for determining the intermediate precision of a measurement method 7 2 3 2 Samples The intermediate precision evaluation shall be performed with control materials The preferred samples are the control materials provided by the manufacturer Alternative control materials may be used if approved for use by the manufacturer of the blood glucose monitoring system 16 IS ISO 15197 2003 Control material shall be prepared according to the instructions for use Sample stability over the evaluation period shall be validated Three samples with glucose concentrations in the intervals specified in Table 2 shall be used The gluc
40. ieve lower glucose concentrations anticoagulated blood samples may be allowed to age until the glucose is depleted to the desired level Table 1 Glucose concentration intervals for repeatability evaluation Glucose concentration Interval mmol L mg dL 8 4 to 13 9 151 to 250 14 0 to 22 2 251 to 400 6 2 to 8 3 111 to 150 7 2 2 3 Reagent system At least 500 reagent system units from at least ten vials or packages are required 7 2 2 4 Meters At least on meters shall be chosen to evaluate the repeatability of the blood glucose monitoring system 7 2 2 5 Evaluation procedure The following procedure is the minimum experimental design to evaluate repeatability It requires ten measurements by each meter of samples from each glucose concentration interval in Table 1 NOTE The procedure may be modified to accommodate multiple reagent lots and or users The samples shall be equilibrated to a temperature of 23 C 5 C and maintained within 2 C of the starting temperature during the experiments The samples shall be gently but thoroughly mixed by inversion before each portion is taken for measurement The reagent system units shall be taken from the same vial package for each meter 15 ISSO 15197 2003 a Assign a vial package of reagent system units to each meter b Take one reagent system unit out of a vial package and apply the sample Record the result A transfer pipette i e not a repeatable meas
41. in capillary blood samples but may express results as either the glucose concentration in blood or the equivalent glucose concentration in plasma Concentrations in this International Standard refer to the type of results reported by the system 3 4 blood glucose meter component of a blood glucose monitoring system that converts the result of a chemical reaction into the glucose concentration of the sample 3 5 commutability of a material ability of a material to yield the same numerical relationships between results of measurements by a given set of measurement procedures purporting to measure the same quantity as those between the expectations of the relationships obtained when the same procedures are applied to other relevant types of material ISO 15194 2002 NOTE For reference materials used to calibrate measurement procedures intended for biological samples other relevant types of material include a large number of samples from healthy and relevantly diseased individuals ISSO 15197 2003 3 6 control material substance material or article intended by the manufacturer to be used to verify the performance characteristics of an in vitro diagnostic medical device EN 375 2001 3 7 information supplied by the manufacturer with the medical device all written printed or graphic matter on a medical device or any of its containers or wrappers or accompanying a medical device relating to the identification technical
42. ities in biological samples Metrological traceability of values assigned to calibrators and controlled materials IEC 60068 2 64 1993 Environmental testing Part 2 Test methods Test Fh Vibration broad band random digital control and guidance IEC 61010 1 2001 Safety requirements for electrical equipment for measurement control and laboratory use Part 1 General requirements IEC 61010 2 101 2002 Safety requirements for electrical equipment for electrical equipment for measurement control and laboratory use Part 2 101 Particular requirements for in vitro diagnostic IVD medical equipment IEC 61000 4 2 2008 Electromagnetic compatibility EMC Part 4 2 Testing and measurement techniques Electrostatic discharge immunity test IEC 61000 4 3 2006 Electromagnetic compatibility EMC Part 4 3 Testing and measurement techniques Radiated radio frequency electromagnetic field immunity test Since revised in various parts and sections International Other Standard IEC 61326 2002 EN 376 2002 EN 13612 2002 EN 13640 2002 IS ISO 15197 2003 Title Electrical equipment for measurement control and laboratory use EMC requirements Information supplied by the manufactures with in vitro diagnostic reagents for self testing Performance evaluation of in vitro diagnostic medical devices Stability testing of in vitro diagnostic reagents The Standard also makes a referen
43. mber and allow it to cool to a temperature of 23 C 2 C and repeat the performance test For those systems in which the reagent system is an integral component of the meter and cannot be separated from the device the high temperature exposure conditions shall be limited to the use conditions specified by the manufacturer 6 11 2 Low temperature test protocol Perform the performance test as described in 6 9 Place the meter in a sealed environmental chamber that can be monitored for internal temperature Decrease the temperature to 20 C 2 C and leave at this temperature for 8 h in the sealed chamber Remove the meter from the environmental chamber allow it to warm until it reaches a temperature of 23 C 2 C and repeat the performance test For those systems in which the reagent system is an integral component of the meter and cannot be separated from the device the low temperature exposure conditions shall be limited to the use conditions specified by the manufacturer 6 12 Equipment humidity exposure test protocol Perform the performance test described in 6 9 Place the meter in a humidity chamber Stabilize the relative humidity noncondensing to 93 3 and a temperature of 32 C 2 C Leave the meter in the humidity chamber for 48 h Remove the meter equilibrate it until it reaches a temperature of 23 C 2 C and a relative humidity of lt 60 for 15 min and repeat the performance test 6 13 Reagent st
44. n the minimum acceptable performance criteria defined in 7 4 1 NOTE 2 There are insufficient samples in each concentration interval to permit valid assessment of acceptability at specific concentrations ISSO 15197 2003 8 User performance evaluation 8 1 General The purpose of the user performance evaluation is to demonstrate that users are able to operate the blood glucose monitoring system given only the instructions and training materials routinely provided with the system and obtain valid glucose results A user performance evaluation shall be performed by the manufacturer prior to placing a new blood glucose monitoring system into commercial distribution NOTE Healthcare professionals who wish to demonstrate the performance of a blood glucose monitoring system in a healthcare setting can consult NCCLS C30 A2I l for guidance Results obtained by the lay user shall be compared to results obtained by a validated glucose measurement procedure as well as to results obtained by a healthcare professional from the same sample using the same blood glucose monitoring system The evaluation plan shall be documented in a detailed pee The requirements specified in EN 13612 apply At least 50 subjects with varying demographics age sex and education level shall be included for each lot Study participants shall meet the requirements of the blood glucose system e g packed cell volume within the system s specified interval
45. oO k OO Oo Oo oo ee k Disclosure to Promote the Right To Information Whereas the Parliament of India has set out to provide a practical regime of right to information for citizens to secure access to information under the control of public authorities in order to promote transparency and accountability in the working of every public authority and whereas the attached publication of the Bureau of Indian Standards is of particular interest to the public particularly disadvantaged communities and those engaged in the pursuit of education and knowledge the attached public safety standard is made available to promote the timely dissemination of this information in an accurate manner to the public Wat sr ata stat aT afar Tat Bl BIS AA Hh TH Mazdoor Kisan Shakti Sangathan Jawaharlal Nehru The Right to Information The Right to Live Step Out From the Old to the New My sO 15197 2003 In Vitro DiAGNOSTIC Test Systems Requirements for Bloos Glucose Monitoring Systems for Self Testing in Managing Diabetes Mellitus MHD 16 Surgical Dressings and Disposable Products Satyanarayan Gangaram Pitroda Bhartrhari Nitisatakam oO k OO Oo oO Oe eo k BLANK PAGE PROTECTED BY COPYRIGHT IS ISO 15197 2003 Wha Wich sq fagr am Tay Gata saada ARa h WAG FAG NI est aH Te Taq A Indian Standard IN VITRO DIAGNOSTIC TEST SYSTEMS REQUIREMENTS FOR BLOOD GLUCOSE MONITORING SYSTEMS
46. of the meter IS ISO 15197 2003 Annex B informative Traceability chain 29 IS ISO 15197 2003 Definition of SI unit for glucose Material 180 g mol Measurement procedure Primary reference measurement procedure Proton NMR and C NMR Primary calibrator NIST SRM 917b 99 7 0 2 glucose Manufacturer s selected measurement procedure Hexokinase method or glucose oxidase method Manufacturer s working calibrator Panel of human blood samples End user s routine measurement procedure BGM system Routine sample Patient s blood specimen Result Glucose concentration in human blood Responsibility NIST NIST Manufacturer Manufacturer End user End user End user NOTE 1 The illustration of a full traceability chain is taken from ISO 17511 4 2 2 h Steps that are not used in this particular calibration scheme are shaded in grey NOTE 2 This example is not intended to represent the only possible traceability chain for a blood glucose monitoring system a NIST SRM917b refers to the Certificate of Analysis issued by the National Institute of Standards and Technology NIST for the standard reference material SRM 917b D glucose dextrose used for calibration in this example Figure B 1 Example of a traceability chain for a factory calibrated blood glucose monitoring system 30 1 2 3 4
47. orage and use testing Conditions for the storage and use of the reagent system and controls shall be defined and validated The requirements specified in EN 13640 apply 13 ISHISO 15197 2003 7 Analytical performance evaluation 7 1 General requirements The analytical performance evaluation shall be conducted as part of the manufacturer s design control system The requirements specified in ISO 13485 apply The performance evaluations shall be performed according to a written protocol The protocol shall specify the experimental details data analysis procedures and acceptance criteria Statistical designs including the numbers of meters reagent units and replicate samples and the acceptance criteria shall be justified in the protocol All components of the system including meters reagent system and accessories shall be representative of product intended for sale The blood glucose monitoring system shall be adjusted prior to the experiment according to the manufacturer s instructions e g via coding chips No adjustments shall be made between replicate measurements unless the manufacturer s instructions specify an adjustment before each measurement The manufacturer s recommended control procedures shall be performed prior to each evaluation NOTE 1 In 7 2 and 7 3 evaluations are design verification activities which are intended to provide assurance that the product has the capability of meeting precision and trueness speci
48. ose concentration of each sample shall be determined using the blood glucose monitoring system Table 2 Glucose concentration intervals for intermediate precision evaluation Glucose concentration mmol L mg dL 5 3 to 8 0 96 to 144 15 5 to 23 3 280 to 420 7 2 3 3 Reagent system A lot or part of a lot shall be examined If a complete lot is not available the part and status of the material shall be recorded Three hundred reagent system units from at least ten vials or packages are required If multiple lots are used the experiment shall be designed so that all results from a single meter are obtained using the same lot of reagent system 7 2 3 4 Meters At least ten meters shall be selected to evaluate the intermediate precision of the blood glucose monitoring system 7 2 3 5 Evaluation procedure The following procedure is the minimum experimental design to evaluate intermediate precision over multiple days It requires one measurement per day of a sample from each glucose concentration interval in Table 2 for 10 days for each of ten meters The procedure may be modified to accommodate multiple reagent lots The reagent system units shall be taken from the same vial package for each sample a Assign a vial package of reagent system units to each meter b Take one reagent system unit out of each vial package and apply the sample Record the result A transfer pipette i e not a repeatable measuring pipette
49. pertain to glucose concentration measurement for the purpose of diagnosing diabetes mellitus address the medical aspects of diabetes mellitus management or apply to measurement procedures with results on an ordinal scale e g visual semiquantitative test methods 2 Normative references The following referenced documents are indispensable for the application of this document For dated references only the edition cited applies For undated references the latest edition of the referenced document including any amendments applies ISO 13485 Medical devices Quality management systems Requirements for regulatory purposes ISO 14971 Medical devices Application of risk management to medical devices ISO 17511 1 In vitro diagnostic medical devices Measurement of quantities in biological samples Metrological traceability of values assigned to calibrators and control materials IEC 60068 2 64 1993 Environmental testing Part 2 Test methods Test Fh Vibration broad band random digital control and guidance IEC 61010 1 2001 Safety requirements for electrical equipment for measurement control and laboratory use Part 1 General requirements IEC 61010 2 101 2002 Safety requirements for electrical equipment for measurement control and laboratory use Part 2 101 Particular requirements for in vitro diagnostic IVD medical equipment 1 To be published ISASO 15197 2003 IEC 61000 4 2 El
50. rence values 25 ISASO 15197 2003 A detailed description of the measurement procedure used to determine the glucose values including its traceability and or equivalence to the manufacturer s selected or standing measurement procedure shall be documented in the protocol Study participants shall not receive additional training instructions assistance or training materials other than those routinely provided with the blood glucose monitoring system Study participants may be given a questionnaire to evaluate their understanding of the system User techniques in operating and maintaining the system applying the sample and reading the result shall be evaluated by the trained healthcare professional participating in the study Results shall be documented in a report 8 4 Evaluation of instructions for use Instructions for use shall be evaluated by the intended users Study participants and healthcare professionals shall review the instructions for use and provide comments regarding the ease of understanding This evaluation may be combined with the testing described in 8 3 or may be conducted separately User comments may be collected via questionnaires or as part of human factors studies 26 ISSO 15197 2003 Annex A normative Additional requirements for electromagnetic compatibility A 1 General This annex specifies minimum requirements for immunity and emissions regarding electromagnetic compatibility EMC
51. res of intermediate precision depend on the stipulated conditions 3 11 label A printed written or graphic information placed on a device or container NOTE Adapted from EN 375 2001 3 12 layperson individual who does not have formal training in a specific field or discipline NOTE 1 Adapted from the definition of lay user in EN 376 2002 NOTE 2 For the purposes of this Intemational Standard a user of a blood glucose monitoring device who does not have specific medical scientific or technical knowledge related to blood glucose monitoring IS ISO 15197 2003 3 13 lot batch one or more components or finished devices that consist of a single type model class size composition or software version that are manufactured under essentially the same conditions and that are intended to have uniform characteristics and quality within specified limits NOTE In Directive 98 79 ECI87 and in European Standards the term batch is preferred 3 14 manufacturer s selected measurement procedure measurement procedure that is calibrated by one or more primary or secondary calibrators and validated for its intended use NOTE ISO 17511 4 2 2 f shows the manufacturer s selected measurement procedure in the traceability chain 3 15 manufacturer s standing measurement procedure measurement procedure that is calibrated by one or more of the manufacturer s working calibrators or higher types of calibrator and validat
52. results were obtained from 100 subjects The data and criteria to be used in determining acceptability are shown in italics Table 4 Example of presentation of system accuracy results for glucose concentration lt 4 2 mmol L 75 mg dL Within 0 28 mmol L Within 0 56 mmol L Within 0 83 mmol L Seer eae 5 mg dL ETEN 10 mg dL Within 15 mg dL 18 40 18 40 45 O 28 40 28 40 70 38 40 95 Table 5 Example of presentation of system accuracy results for glucose concentration gt 4 2 mmol L 75 mg dL Within 5 Ya Within 10 Within 15 Yo Within 20 36 160 22 78 160 49 136 160 85 156 160 97 7 4 3 System accuracy assessment Acceptability of the blood glucose monitoring system shall be determined using all of the 200 results obtained from the 100 subjects including any results identified as statistical outliers The number of acceptable results at glucose concentrations lt 4 2 mmol L lt 75 mg dL shall be added to the number of acceptable results at glucose concentrations gt 4 2 mmol L gt 75 mg dL to determine the number of acceptable results NOTE 1 In the example in 7 4 2 38 of 40 hypoglycaemic samples were within 0 83 mmol L 15 mg dL at concentrations lt 4 2 mmol L lt 75 mg dL and 156 of the 160 samples with glucose concentrations gt 4 2 mmol L gt 75 mg dL were within 20 of the reference values Therefore 194 of 200 samples 97 0 Yo were withi
53. rformance tests NOTE 2 The tests described in 6 2 to 6 8 are type tests 6 1 2 Meters and reagent systems Meters and reagent systems shall be representative of routine production units For performance tests at least ten meters shall be used in each test For type tests three meters should be used in each test 6 1 3 Acceptance criteria Acceptance criteria for bias and repeatability for the performance tests in 6 10 to 6 13 should be derived from the system accuracy criteria in 7 4 The rationale shall be documented in the protocol The blood glucose monitoring system shall pass the acceptance criteria in each test protocol Alternatively the system shall be rendered nonfunctional and shall not display a numerical glucose result Failures to meet acceptance criteria shall be investigated 6 2 Protection against electric shock The requirements specified in IEC 61010 1 2001 Clause 6 apply 6 3 Protection against mechanical hazards The requirements specified in IEC 61010 1 2001 Clause 7 apply 6 4 Electromagnetic compatibility The requirements specified in IEC 61326 apply In addition the requirements specified in Annex A apply 6 5 Resistance to heat The requirements specified in IEC 61010 1 2001 Clause 10 apply 6 6 Resistance to moisture and liquids The requirements specified in IEC 61010 1 2001 11 1 11 2 and 11 3 apply 11 IS ISO 15197 2003 6 7 Protection against liberated gases explosion and implosion
54. sed for calibration blood or plasma i the measurement procedure to be followed including the sequence of steps to prepare the reagent system and execute the measurement the timing between the individual steps if applicable j the detailed control procedures and control materials to be used to verify that the blood glucose monitoring system is operating within its performance specifications The language s of the country in which the reagents and control materials are distributed shall be used additional languages are optional Required information regarding reagents and or control materials may be included in the instructions for use for the instrument or system if the manufacturer of the instrument or system is the same as the manufacturer of the reagents If there is a change in this information reagent labels should be used to notify the user and the changed information shall be placed in the instructions for use for the reagent system 10 ISMSO 15197 2003 6 Safety and reliability testing 6 1 General requirements 6 1 1 Protocol Experimental designs data analysis procedures and acceptance criteria shall be described in a protocol The protocol shall specify the number of meters reagent units and replicate measurements per meter For performance tests the protocol shall include statistical rationale Specified testing requirements are minimum requirements NOTE 1 The tests described in 6 9 to 6 12 are pe
55. tine glucose measurement procedure e g in a hospital or outpatient clinic laboratory that is validated for precision and trueness by comparison to the manufacturer s selected or standing measurement procedure may be used to assign the reference values A detailed description of the measurement procedure used to determine the reference values including its traceability and or equivalence shall be documented in the protocol 7 3 1 2 Samples The system accuracy evaluation shall be performed with at least 100 fresh capillary blood samples each with sufficient volume to be measured by two different meters and at least in duplicate by the manufacturer s measurement procedure Exclusion criteria such as packed cell volume haematocrit shall be based on the manufacturer s instructions for use 18 IS ISO 15197 2003 Capillary blood samples shall be collected by skin puncture e g fingerstick prepared and processed according to the instructions for use including sample pretreatment if required Sample containers designed for the collection of capillary blood should be used In some cases a second skin puncture may be necessary to obtain sufficient sample volume to complete the protocol It may be difficult to obtain a sufficient number of fresh capillary blood samples with very low and very high glucose concentrations In these cases modified capillary blood samples in which the glucose concentration is elevated or lowered may
56. to the device e conditions for storage and handling if appropriate f areference to the user manual or instructions for use Where appropriate information on the label should take the form of symbols Symbols shall conform to applicable regulations and International Standards All symbols shall be described in the information supplied with the blood glucose meter 5 2 Instructions for use for the blood glucose monitoring system The instructions for use shall be presented in a clear and concise manner using plain terminology that is readily understood by a layperson The information shall be well organized and easy to read The print shall be large e g 12 point Courier and the content shall be readily understandable by persons without a scientific or technical background Symbols and illustrations shall be used where appropriate The instructions for use shall clearly state what actions to take if the verification indicates an invalid result The language s of the country in which the blood glucose monitoring system is distributed shall be used Additional languages are optional The instructions for use shall include the following information a name or trade name and address of the manufacturer the name and address of the distributor if applicable in the European Union Directive 98 79 ECI3 requires the name and address of the authorized representative if the manufacturer is not located in the European Union and how to
57. tructions for use in which the user enters a number inserts a code strip or chip etc so that the system achieves acceptable performance characteristics 4 Design and development 4 1 General requirements The requirements specified in ISO 13485 apply NOTE Clause 6 7 2 and 7 3 describe design verification activities which are intended to provide assurance that the system has the capability of meeting its precision trueness safety and reliability specifications Clause 8 describes design validation activities which are intended to provide assurance that system accuracy meets user requirements 4 2 Safety The requirements specified in IEC 61010 1 and IEC 61010 2 101 apply 4 3 Traceability The requirements specified in ISO 17511 apply to the manufacturer s calibration process NOTE 1 The manufacturer s selected or standing measurement procedure may measure glucose in either blood or plasma samples If plasma samples are used the blood glucose monitoring system may report results as plasma glucose equivalents even though the samples measured by the bloud glucose monitoring system are blood NOTE 2 The traceability chain should include as few steps as practical to minimize combined uncertainty NOTE 3 A traceability chain for a typical factory calibrated blood glucose monitoring system is shown in Annex B This example is not intended to represent the only possibility of a suitable traceability chain 4 4 Ergonomic human factor aspects
58. uring pipette capable of delivering sample volumes within the manufacturer s recommended interval may be used to simulate routine sample application c Repeat step b nine more times using the same meter d Using the same sample repeat steps b and c with each of the nine remaining meters and vials or packages This results in a total of ten measurements per sample per meter e Take the next sample and repeat steps a to d f Calculate the mean value the standard deviation and the coefficient of variation CV for each meter from the ten measurements g Calculate the grand mean the pooled variance the pooled standard deviation with 95 confidence interval and the pooled CV NOTE The standard deviation and CV are measures of repeatability The experiment may be designed so as to obtain the repeatability standard deviation as well as other variance components by analysis of variance instead of following steps f and g Aliquots shall be removed from each sample immediately before the first and immediately after the last measurement by the blood glucose monitoring system for measurement minimum in duplicate by the manufacturer s selected or standing measurement procedure If these results demonstrate the effect of drift based on predetermined stability criteria e g change between the first and last results gt 4 at glucose gt 5 5 mmol L 100 mg dL or gt 0 22 mmol L 4 mg dL at glucose lt 5 5 mmol L 100 mg dL t
59. verly demanding performance requirements would cause manufacturers to focus design improvements on analytical performance at the expense of other important attributes For example frequency of testing by diabetic patients can be as important as the accuracy of an individual result and greater convenience of glucose self testing improves patient compliance The system accuracy criteria define the minimum acceptable performance of a blood glucose measuring device intended for self monitoring Future advances in technology are expected which should result in improved performance of glucose monitoring devices Such performance improvements will be driven by the competitive marketplace particularly through reduction of dependence on user technique Requirements that are unique to self monitoring devices for blood glucose including the content of information supplied by the manufacturer are addressed in this standard General requirements that apply to all in vitro IS ISO 15197 2003 diagnostic medical devices and are covered by other standards for example IS 15579 and ISO 14971 are incorporated by reference where appropriate Although this standard does not apply to measurement procedures with results on an ordinal scale for example visual semi quantitative measurement procedures it may be useful as a guide for developing procedures to evaluate the performance of such systems The text of ISO Standard has been approved as suitable for pu
60. vision of Clinical Laboratory Devices March 1998 CLARKE W L et al Evaluating clinical accuracy of systems for self monitoring of blood glucose Diabetes Care 10 5 1987 pp 622 628 31 ISASO 15197 2003 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 32 PARKES J L et al A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose Diabetes Care 23 8 2000 pp 1143 1148 SKEIE S THUE G and SANDBERG S Patient derived quality specifications for instruments used in self monitoring of blood glucose Clinical Chemistry 47 1 2000 pp 67 73 ISO 3534 1 1993 Statistics Vocabulary and symbols Part 1 Probability and general statistical terms ISO 5725 1 Accuracy trueness and precision of measurement methods and results Part 1 General principles and definitions ISO 5725 2 Accuracy trueness and precision of measurement methods and results Part 2 Basic method for the determination of repeatability and reproducibility of a standard measurement method ISO 5725 3 Accuracy trueness and precision of measurement methods and results Part 3 Intermediate measures of the precision of a standard measurement method ISO 14969 1999 Quality systems Medical devices Guidance on the application of ISO 13485 and ISO 13488 International vocabulary of basic an

IS/ISO 15197 (2003): In Vitro DiAGNOSTIC Test Systems

Contents

Download Pdf Manuals

Related Search

Related Contents